Key Highlights
- Phase 3 trial of Novo Nordisk’s oral GLP-1 medication achieved its primary endpoint in young patients with type 2 diabetes
- Participants experienced a 0.83 percentage point greater reduction in average blood sugar compared to placebo during the 26-week study period
- Study enrolled 132 participants ranging from 10 to 17 years of age
- This marks the first oral GLP-1 therapy to demonstrate efficacy in pediatric populations
- Company anticipates submitting for regulatory clearance in the United States and European Union during H2 2026
Novo Nordisk announced Thursday that its oral semaglutide medication successfully demonstrated blood sugar reduction capabilities in young patients diagnosed with type 2 diabetes, based on data from a completed phase 3 clinical study.
The 26-week study enrolled 132 participants spanning ages 10 through 17. Those receiving the active medication experienced average blood sugar reductions exceeding placebo by 0.83 percentage points.
Novo Nordisk characterized this outcome as statistically significant, confirming the study achieved its primary efficacy measure.
This clinical program represents the inaugural testing of an oral GLP-1 medication in pediatric and adolescent populations. Presently, regulatory authorities have approved no oral GLP-1 therapies for this demographic.
The medication currently receives marketing authorization as Rybelsus and Ozempic pill for adult populations. The oral formulation of Ozempic is anticipated to reach U.S. pharmacies during Q2 2026.
Historically confined to adult populations, type 2 diabetes now affects younger demographics with increasing frequency. Centers for Disease Control data indicates approximately 364,000 American children and adolescents under age 20 currently live with diagnosed diabetes.
Existing Pediatric Treatment Landscape Remains Constrained
Clinicians managing younger patients face limited therapeutic choices. Metformin serves as the initial treatment approach, though it proves inadequate for glycemic management in approximately 50 percent of adolescent cases.
Insulin therapy provides another avenue, though it introduces complications including hypoglycemic events and unwanted weight increases. An oral medication with favorable tolerability would address a significant unmet medical need.
Martin Holst Lange, chief scientific officer at Novo Nordisk, noted the dramatic rise in type 2 diabetes diagnoses among younger populations during the previous twenty years.
“Oral semaglutide is an effective treatment option for children and adolescents with Type 2 diabetes who require glycaemic control beyond that provided by the current standard of care,” Lange said.
Submission Timeline Set for Second Half of 2026
The Danish pharmaceutical manufacturer intends to pursue label expansion for both Rybelsus and the Ozempic pill formulation to encompass pediatric and adolescent indications in American and European markets during the latter portion of 2026.
Regulatory approval would establish semaglutide as the inaugural oral GLP-1 therapy authorized for younger patient populations.
Safety data from the pediatric trial aligned with observations from previous semaglutide studies conducted in adult cohorts.
Gaining approval would broaden Novo’s semaglutide product portfolio into an entirely new demographic segment, potentially strengthening the company’s competitive position against Eli Lilly (LLY) in metabolic disease markets.
The pharmaceutical company expects to complete regulatory submission processes in both jurisdictions before year-end 2026.
